Parse Biosciences, a QIAGEN company and the leading provider of scalable and accessible single-cell sequencing solutions, today announced the commercial availability of Evercode (TM) Whole ...
Machine Learning and Single-Cell Technology Combined to Drive High-Performance Cell Line Development
The integrated approach is designed to adapt to the evolving needs of new therapeutic modalities, delivering both speed and performance.
Collaboration pairs robust synthetic biology platform with massive scale single cell sequencing to overcome long-standing challenges in variant mapping Parse Biosciences, the leading provider of ...
Morning Overview on MSN
New spatial transcriptomics maps gene activity across whole bodies
A wave of spatial transcriptomics studies has produced gene-expression atlases that span entire organs and whole organisms, ...
New chemistry reduces barriers to scaling single-cell studies across research settings Launch planned for March 2026, available across Evercode Whole Transcriptome product line Parse Biosciences, a ...
Rare cancers encompass a heterogeneous group of malignancies characterized by low incidence and prevalence but, often, disproportionately high mortality ...
A new single-cell atlas shows how epigenetic changes reshape brain cells during aging, revealing genomic instability, ...
Ampullary adenocarcinoma: What is the best approach? Insights from a large retrospective series. Evaluating the efficacy of tyrosine kinase inhibitors and other targeted therapies in ...
X-Cell generalizes to new biological contexts and breaks barriers as the first scaling law demonstrator in the virtual cell domain.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results